Blue Water Acquisition — Clarus Therapeutics — SPAC Merger (April 2021)
29 slides from Blue Water Acquisition's SPAC merger presentation, Apr 27, 2021
Slide 1: Corporate Presentation April 2021
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 1 CORPORATE PRESENTATION APRIL 2021 INNOVATING FOR BETTER HEALTH
Slide 2: Disclaimer
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 2 DISCLAIMER This presentation (“Presentation”) is for informational purposes only and is being furnished solely for the purpose
Slide 3: Disclaimer (Cont'd)
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 3 DISCLAIMER (CONT’D) This Presentation does not purport to summarize all of the conditions, risks and other attributes of an in
Slide 4: Clarus Leadership Team
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 4 ROBERT DUDLEY, PH.D President & CEO • Over 30 years experience in TRT field • Clarus co - founder • Extensive R&D experience a
Slide 5: Clarus Leadership Team (cont.)
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 5 FRANK JAEGER, MA, MBA Chief Commercial Officer • Significant Medical Affairs experience • Multiple therapeutic area experience
Slide 6: Blue Water Leadership Team and Board
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 6 • 25+ years of experience in healthcare • Founded or led 8 healthcare and pharmaceutical companies (i.e. Innovative Biosensors
Slide 7: Investment Thesis
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 7 7 1 2 5 3 4 JATENZO is an FDA approved, first in class and only oral testosterone replacement therapy (“TRT”) of its kind to c
Slide 8: The JATENZO Opportunity
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 8 THE JATENZO OPPORTUNITY
Slide 9: Hypogonadism Overview
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 9 9 HYPOGONADISM OVERVIEW TESTOSTERONE DEFICIENCY IN MEN (HYPOGONADISM) IS A LARGE AND ATT RACTIVE MARKET OPPORTUNITY Male Hypog
Slide 10: Pre-JATENZO Treatment Landscape
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 10 2014 2010 2003 Earlier TIMELINE OF SELECT TRT FDA APPROVALS 1995 1996 1997 1998 1999 2000 2001 2002 2015 2016 2017 2018 2019
Slide 11: Importance of an Oral T Option
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 11 11 Current Non - oral Treatments Pose Administration Challenges The Cycle of Discontinuation More than 95,000 men change TRTs
Slide 12: The JATENZO Opportunity: First Oral T of Its Kind
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 12 12 THE JATENZO OPPORTUNITY FIRST ORAL T OF ITS KIND APPROVED BY FDA – A LONG - AWAITED ADVANC E! CONVENIENT • Easy - to - swa
Slide 13: JATENZO Product Differentiators
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 13 13 JATENZO PRODUCT DIFFERENTIATORS A SAFE ORAL WITHOUT LIVER TOXICITY ADDRESSES COMMON CONCERNS SEE N WITH INJECTIONS AND GEL
Slide 14: Symptom Improvement
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 14 14 SYMPTOM IMPROVEMENT JATENZO INCREASES FREE TESTOSTERONE AND IMPROVES CLASSIC SIGNS A ND SYMPTOMS ASSOCIATED WITH HYPOGONAD
Slide 15: JATENZO Safety Profile Consistent with TRT Class
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 15 Adverse Reactions ≥ 2% in 4 - Month Pivotal Trial of JATENZO JATENZO WAS SHOWN TO BE SAFE AND WELL - TOLERATED JATENZO SAFETY
Slide 16: Health Care Providers and Patients Like JATENZO
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 16 “All of our TRT patients ask about different options. This is amazing. Finally.” “This is an innovative game changer, and thi
Slide 17: TRT Market Performance in 2020
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 17 200,000 300,000 400,000 500,000 600,000 700,000 800,000 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Oct-19
Slide 18: Focused Targeting
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 18 FOCUSED TARGETING CLARUS IS ENGAGING THE KEY TRT HCPS AND THE PATIENTS THEY TREAT Endocrinologists, Urologists, Primary Care
Slide 19: Patient Support and Savings
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 19 PATIENT SUPPORT AND SAVINGS MOST COMMERCIAL COVERED PATIENTS WILL PAY $0 FOR THEIR PRESCRIPTION 19 19 TRT Market (Dec. 2020)
Slide 20: Commercial Access – Market Comparison
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 20 fgfg COMMERCIAL ACCESS – MARKET COMPARISON JATENZO HAS COMPETITIVE COVERAGE THROUGHOUT 2021 20 0.00% 10.00% 20.00% 30.00% 40.
Slide 21: JATENZO Has Consistently Grown Since Launch
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 21 21 2020 DEMAND SALES JATENZO HAS CONSISTENTLY GROWN SINCE LAUNCH DESPITE THE PANDEMIC AND COMMERCIAL PAYOR COVERAGE JATENZO T
Slide 22: Empower the Patient: DTC and Spokesperson
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 22 EMPOWER THE PATIENT: DTC AND SPOKESPERSON 22 DTC Spokesperson • Launch Date: Q4/2021 • Launch Date: Q4/2021 • In Active Negot
Slide 23: Expanding the Sales Force
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 23 EXPANDING THE SALES FORCE CREATES THE NATIONAL FOOTPRINT TO DELIVER ON BRAND STRATEGIES – MAXIMIZING SALES IMPACT • Sales For
Slide 24: Potential Growth Areas
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 24 POTENTIAL GROWTH AREAS 24 • JATENZO out - licensing opportunities to recognize incremental and ongoing revenue with: • Europe
Slide 25: Expansion Opportunities for JATENZO
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 25 EXPANSION OPPORTUNITIES FOR JATENZO 25 2021 2022 Product Company Indication Q1’21 Q2’21 Q3’21 Q4’21 Q1’22 Q2’22 Q3’22 Q4’22 J
Slide 26: Transaction Summary
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 26 Transaction Summary
Slide 27: Transaction Summary: Clarus + Blue Water
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 27 TRANSACTION SUMMARY 27 1. Exact amount dependent on final Investment amounts and redemptions at de - SPAC. • Business Combina
Slide 28: Pro Forma Equity Ownership
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 28 28 Source: Company internal data 1. The amounts from the various sources of cash may change based on (i) the amount of Public
Slide 29: Key Takeaways
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 29 2 9 Right Team Highly relevant TRT experience with a track record of success Attractive Opportunity A high - growth category